Lepu Medical: mergers and acquisitions more than 30 times only to set up a "heart" of hope

Casual simple white shirt with dark blue jeans, face always with a smile, words light and free, no tired years of hard work, although the previous day in the middle of the night only returned to Beijing on business - this is the Lepu medical boss, chairman Pu Zhongjie recently interviewed to give reporters the first impression.
nearly 20 years since its establishment, it has caught up with the good times of reform and opening-up and seized new opportunities in the capital market. Pu Zhongjie said that the concept of Lepu Medical Development is to focus on serving the community of cardiovascular patients. Pu Zhongjie like to tell reporters, and like telling himself: "The cardiovascular future is likely to affect the pharmaceutical industry, Lepu Medical must be a leader." " To build a cardiovascular industry chain
mentioned Lepu Medical, people in the industry will think of its leading position in the field of medical devices, you can look at this enterprise, you will find that it has long been not limited to medical devices, the frequency of its mergers and acquisitions, the scope of expansion is amazing.
was founded in 1999, when only the first generation of heart stents was developed independently. With a single product, it's hard to get a head start in the medical device field. Because of the huge losses, the company had to suspend sales of products and concentrate on improving technology. It wasn't until six years later, when Lepu Medical developed the more advanced stent system Partner, and in 2007 gained the ability to produce conveyors on a large scale through independent research and development, that it beed passively turned to active.
in accordance with the "end-to-end" principle, Lepu Medical carefully designed the future to do the whole platform concept, and began a long "fill-in" road. The company has acquired Tiandi and Concorde (catheters, wire guides, tubes and other supporting equipment or intervention accessories), Shanghai shape (first-heart intervention blocker), improve the supporting capacity of interventional medical products.
2009, Lepu Medical successfully landed on the GEM. The company already has two popular medical device products - a drug stent for coronary heart disease and a blocker for congenital heart disease. But Pu Zhongjie is still not satisfied. He found that only a few companies in the health industry achieved stable and sustainable growth, and that most could not escape the rhythm of the growth cycle. Mr Pu concluded: "They are not long-term growth companies, but obvious cyclical ones." The
declined since 2010 as a result of slowing growth in the cardiovascular high-value consumables industry. In the face of difficulties, Lepu Medical took advantage of the industry crisis to buy low-cost friends, from the field of intervention into pacemakers and other related tracks: the acquisition of Wei Jinfan Medical (now "Lepu Equipment"), access to angiotic technology;
2014, Pu Zhongjie became the actual controller of Lepu Medical, continued to improve the platform development strategy, and began to enter the cardiovascular medicine market from the medical device field. The company has acquired 60% of the shares of Xin Shuaike (now "Lepu Pharmaceuticals"), Haihetian and Xindonggang (now "Zhejiang Lepu Pharmaceuticals"), to further improve the cardiovascular drug product line.
March 2016, Lepu Medical acquired the remaining 40% stake in Lepu Pharmaceuticals for nearly 720 million yuan, acquiring its core product, hydrochlorochloropolyte tablets of hydrochloride sulfate, an anti-thrombosis base drug. In March 2018, Lepu won a 45% stake in New Donggang for 1.05 billion yuan, expanding its stake to 98.95 percent, with the intention of obtaining calcium tablets for its treatment of coronary heart disease drug Atovastatin.
looking back through more than 30 mergers and acquisitions, from a single business to the cardiovascular industry chain, Pu Zhongjie believes that the company has always been around the main industry investment, did not enter the non-related areas, did not do wealth management products. Companies adhere to investment products, investment in the future, long-term layout, hedging in different areas, to maintain a 30% growth rate.
Lepu Medical's mergers and acquisitions are almost all strategic, in order to enter a new field, through mergers and acquisitions to obtain access certificates, and then carry out the integration of their own resource advantages, to achieve research and development upgrades, product butterfly change, and ultimately form the entire industrial chain of the mesh economic structure. At the same time, almost every merger and acquisition, Lepu Medical has made full preparations, once the merger is successful, it quickly integrate new resources into new areas, to play the value of resource upgrading brought about by mergers and acquisitions.technology and market "moth" and high-
technology is a natural barrier to the medical industry. Lepu Medical took several years of extended mergers and acquisitions to acquire the cardiovascular field of overweight pounds, heavy weights, sub-segmented leading drugs, from the technical and market dimensions, to further build a "moth."
fully biodegradable vascular stent (NeoVas) is a technological revolution in the field of cardiovascular interventional therapy at Lepu Medical. In the past, traditional metal stents were vascular re-through technology, while fully biodegradable stents could be regarded as vascular reconstruction techniques that restore the function of blood vessels themselves. NeoVas is in the registration review phase and is expected to receive approval by the end of the year. The product is about 3 years earlier than the main competitor and is expected to become the world's first fully biodegradable bracket product for a wide range of applications.
's fully biodegradable blocker has successfully completed the world's first successful implantation, the company has entered the world's leading ranks, and its clinical trials are advancing rapidly. The roll-out of this technology will completely address the risk of growth caused by metal-degradable sealers implanted in children today, bringing great hope to children with congenital diseases.
AI technology to the electrostat graph diagnostic analysis is another revolution in the medical field, the company AI-ECG Platform has been accepted by the FDA registration, the declaration of domestic registration and CE certification work is being advanced, product diagnostic projects covering major cardiovascular diseases. Pu Zhongjie proudly said that AI-ECG Platform is the first AI medical technology to realize industrialization in China, with an accuracy rate of more than 95%, and has been praised by international experts.
addition to medical devices, Lepu Medical has increased research and development and investment in cardiovascular medicine. According to Pu Zhongjie, the company's existing overweight pounds, heavy weight, market segments of leading drugs, are the company through extended mergers and acquisitions. At present, the company in the whole field of cardiovascular disease has three market capacity of more than 10 billion yuan overweight pounds of products, three markets capacity of 3 billion yuan to 5 billion yuan of heavy products, nearly 10 market capacity of 1 billion yuan of leading products. Products cover the entire field of cardiovascular disease treatment such as hypoglycemia, blood pressure reduction, lipid reduction and anticoagulant.
Pu Zhongjie believes that in the context of health care charges, relying on a single variety of enterprises will become less and less competitive. Lepu Medical advance layout of the full range, full variety of cardiovascular disease medication, in the context of the national generic drug consistency evaluation, will help enterprises usher in the same starting line with the current advantages of enterprises to start again.layout of cancer immunotherapy
Pu Zhongjie said, the medical field of the best targets have been "the main flower", so to enter the era of the enterprise's own research and development capabilities.
third-quarter report, research and development expenses from January to September this year were 26.38243 million yuan, up 71.86 percent year-on-year. "There has been less innovation in the cardiovascular sector in recent years, and Lepu Healthcare is considering how to integrate to make a bigger impact. Large-scale mergers and layouts are over, and the future is complementary. Pu Zhongjie said that last year, the company entered the field of cancer, has invested a total of nearly 1 billion yuan.
and his team realized that the future of rapid growth requires the search for new growth momentum to help, tumor immunotherapy is the company identified as the long-term development of the new momentum. The company has focused on investing in a number of mainstream technology pathways worldwide in oncology immunotherapy and precision diagnostic therapy programs, and Lepu Bio, which took part earlier this year, is the industrialization platform for implementing this new dynamic energy.
Currently, Lepu Medical has invested in Regency Biopharmaceuticals, Gritstone Oncology, Genapsys, Quanterix, Rgenix and many other domestic and foreign companies, and their research involves PD-(L)1 and other tumor immuno-target drugs, DNA/RNA sequencing, therapeutic cancer vaccines for new antigens, and ultra-high precision protein detection techniques.
October 28 this year, the foundation ceremony of Lepu Biotech Co., Ltd. was held in Pujiangyuan, Yizhuang Industrial Zone, Shanghai, and plans to build a comprehensive industrial base with supporting facilities such as research and development and production. The implementation of this project demonstrates Lepu's firm determination in the field of tumor immunotherapy, which will effectively enhance Lepu's overall strength in this field in the future.
is also the first professional prescription drug manufacturer to set up a separate OTC marketing team to deep into the drug retail market. Since 2014, Lepu Medical has established Lepu Cardiovascular Network Hospital with distinctive features, and has co-built pharmacy clinics in nearly 400 large pharmacy stores in 21 provinces across the country. This strengthens the company's relationship with the drugstore chain and allows patients with cardiovascular disease to be managed locally as quickly as possible, providing big data support for the smart healthcare of the future.
That year by a heart stent, Lepu Medical after many years of operation, enterprises more and more have "star phase": in the upstream layout of in-body diagnostic equipment, responsible for cardiovascular gene screening, diagnosis;
truly visionary companies understand what should be constant and what should be brave to change. Lepu Medical's growth experience foreshadows a brighter future. (Shanghai Securities News)